AlphAIAlphAI — Financial news for AI agents
investing.comNOV 42 min read

Medline Q3 2026 slides: sales rise 10%, shares jump 15% on guidance

Medline Industries reported Q3 2026 net sales of $7.9B, up 10.4%, and adjusted EBITDA of $960M, up 11.8%. Shares rose 15.58% on raised guidance and a $1B share repurchase program. Organic sales grew 10.5%, with segment growth varying. Higher costs and lower-margin distribution impacted margins. The company expects continued growth and improved market share.

Original reporting
investing.com
Published Nov 4, 2026, 5:53 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 6:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$MDLN
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

Low
01

Why it matters

The earnings beat and new $1 B buyback program signal strong cash generation, but lack of a tradable ticker limits actionable trading opportunities.

02

Market read

The report is material for sector analysts but offers no direct trade on public markets.

03

What to watch

Potential competitive pressure from larger public peers could temper optimism.

Relevance 7/10Novelty 8/10Timing: today

Background

Medline Industries, a private healthcare supply‑chain firm, released its Q3 2026 results and raised full‑year guidance.

Market effects

Sector

Highlights growth in healthcare supply chain and distribution sector.

Regional

U.S. healthcare suppliers may see modest upside.

Global

Limited to investors tracking private healthcare providers.

Counterpoint

What could challenge this read

Without a public listing, the earnings may have little direct market impact.

Key entities

  • company
    Medline Industries

    Private healthcare supply‑chain company reporting Q3 2026 results.

Read at source← All news

StoryMedline raises full‑year organic sales outlook, launches $1 billion share buyback

Also covered by

5 outlets

Related articles

NOV 4
$MDLNHighAI 8/10

Medline: Q3 Earnings Snapshot

Medline Inc. (MDLN) reported Q3 earnings of $195 million, or 22 cents per share, beating analyst estimates of 34 cents per share. Adjusted earnings were 44 cents per share. Revenue was $7.86 billion, exceeding forecasts of $7.69 billion, according to Zacks Investment Research.

finance.yahoo.com2 min
NOV 4
$MDLNMedAI 8/10

Medline Q3 Sales Rise 10.4% to $7.9 Billion; Net Income Falls 1.2%

Medline reported Q3 2026 net sales of $7.856B, up 10.4% YoY, but net income fell 1.2% to $318M. Adjusted EBITDA rose 11.8% to $960M. The company raised its full-year organic sales growth outlook to 10.0%-10.5% and reaffirmed Adjusted EBITDA guidance of $3.3B-$3.4B. Medline also announced a $1B share repurchase program and prepaid $750M of its 2033 term loan.

tradingview.com2 min
NOV 4
$MDLNHighAI 9/10

Medline Reports Third Quarter and Nine Months 2026 Results

Medline Inc. (MDLN) filed an SEC Form 8-K — Results of Operations and Financial Condition. November 4, 2026 Medline Reports Third Quarter and Nine Months 2026 Results • Third quarter net sales of $7.9 billion, an increase of 10.4% • Third quarter net income of $318 million, a decrease of 1.2% • Third quarter Adjusted EBITDA 1 of $1.0 billion, an increase of 11.8% • Nin

SEC EDGAR 8-K2 min